- Home
- BIIB vs ZBRA Comparison
BIIB vs ZBRA Comparison
Compare BIIB & ZBRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ZBRA
- Stock Information
- Founded
- BIIB 1978
- ZBRA 1969
- Country
- BIIB United States
- ZBRA United States
- Employees
- BIIB N/A
- ZBRA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ZBRA Industrial Machinery/Components
- Sector
- BIIB Health Care
- ZBRA Industrials
- Exchange
- BIIB Nasdaq
- ZBRA Nasdaq
- Market Cap
- BIIB 24.2B
- ZBRA 14.7B
- IPO Year
- BIIB 1991
- ZBRA 1991
- Fundamental
- Price
- BIIB $168.52
- ZBRA $239.14
- Analyst Decision
- BIIB Buy
- ZBRA Buy
- Analyst Count
- BIIB 24
- ZBRA 7
- Target Price
- BIIB $174.62
- ZBRA $346.29
- AVG Volume (30 Days)
- BIIB 1.8M
- ZBRA 843.9K
- Earning Date
- BIIB 10-30-2025
- ZBRA 10-28-2025
- Dividend Yield
- BIIB N/A
- ZBRA N/A
- EPS Growth
- BIIB N/A
- ZBRA 34.78
- EPS
- BIIB 10.97
- ZBRA 9.93
- Revenue
- BIIB $10,065,900,000.00
- ZBRA $5,255,000,000.00
- Revenue This Year
- BIIB $2.97
- ZBRA $10.10
- Revenue Next Year
- BIIB N/A
- ZBRA $9.79
- P/E Ratio
- BIIB $15.27
- ZBRA $24.24
- Revenue Growth
- BIIB 4.77
- ZBRA 12.87
- 52 Week Low
- BIIB $110.04
- ZBRA $205.73
- 52 Week High
- BIIB $175.86
- ZBRA $427.76
- Technical
- Relative Strength Index (RSI)
- BIIB 74.64
- ZBRA 28.53
- Support Level
- BIIB $151.83
- ZBRA $254.74
- Resistance Level
- BIIB $157.79
- ZBRA $264.97
- Average True Range (ATR)
- BIIB 5.59
- ZBRA 10.58
- MACD
- BIIB 1.37
- ZBRA -2.63
- Stochastic Oscillator
- BIIB 95.37
- ZBRA 3.46
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About ZBRA Zebra Technologies Corporation
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.